1. A 61-year-old man with a prior myocardial infarction two years ago and heart failure with reduced ejection fraction (LVEF 34%) presents with symptomatic persistent atrial fibrillation that has not responded to rate control with metoprolol. His CrCl is 55 mL/min and baseline QTc is 428 ms. His cardiologist considers antiarrhythmic therapy for rhythm control. Which of the following is the most appropriate selection?
A) Flecainide 100 mg twice daily with a concurrent AV nodal blocking agent, because his LVEF of 34% is above the absolute cutoff of 30% and his QTc is within the acceptable range for Class Ic initiation
B) Propafenone 150 mg three times daily, because its additional beta-blocking properties provide both rhythm control and rate control simultaneously, avoiding the need for a separate AV nodal blocking agent in this patient with structural heart disease
C) Amiodarone, because Class Ic agents (flecainide, propafenone) are contraindicated by the CAST principle in this patient with structural heart disease from prior MI and HFrEF regardless of ejection fraction; dronedarone is contraindicated by HFrEF; sotalol requires reassessment given the CrCl; and amiodarone is hepatically cleared with established safety in HFrEF
D) Quinidine 200 mg three times daily with digoxin for rate control, because Class Ia agents are not subject to the CAST contraindication and quinidine's antimuscarinic effect is counteracted by the concurrent digoxin
E) Mexiletine 150 mg three times daily, because Class Ib agents are not contraindicated in structural heart disease and mexiletine's ability to shorten action potential duration will help suppress the ectopic atrial triggers responsible for persistent atrial fibrillation
ANSWER: C
Rationale:
This question requires systematic elimination of options using the contraindications established for each antiarrhythmic class.
Option A: Option A is incorrect: flecainide is absolutely contraindicated by the CAST principle in any patient with structural heart disease from prior MI or HFrEF regardless of current ejection fraction; no ejection fraction threshold makes Class Ic agents safe in post-MI structural disease.
Option B: Option B is incorrect: propafenone carries the identical CAST-derived contraindication as flecainide; its additional beta-blocking properties do not override the structural heart disease contraindication. Dronedarone is contraindicated in HFrEF with reduced ejection fraction (ANDROMEDA trial). Sotalol at CrCl 55 mL/min would require dose reduction to 80 mg twice daily and careful in-hospital monitoring initiation, but more importantly sotalol in HFrEF with structural heart disease carries significant risk ; it is generally avoided in this population. Amiodarone is the appropriate choice: it is hepatically cleared (unaffected by the CrCl of 55 mL/min), demonstrated mortality neutrality in HFrEF in the SCD-HeFT trial, and carries no structural heart disease contraindication. Its multi-organ toxicity profile requires systematic monitoring, but this does not constitute a contraindication in a patient where other agents are excluded.
Option D: Option D is incorrect: while Class Ia agents are not subject to the identical CAST-derived contraindication as Class Ic agents, quinidine carries significant proarrhythmic risk (TdP from QT prolongation), is associated with drug interactions including inhibition of CYP2C9 (cytochrome P450 2C9), and is not a preferred first-line choice in structural heart disease; it is not the appropriate selection when amiodarone is available.
Option E: Option E is incorrect: mexiletine is a Class Ib agent used for ventricular arrhythmia suppression and LQT3, not for atrial fibrillation rhythm control; Class Ib agents do not have established efficacy for AF and are not used for this indication.
2. A 47-year-old woman with paroxysmal atrial fibrillation and no structural heart disease was started on flecainide 100 mg twice daily five days ago without a co-prescribed AV nodal blocking agent. She now presents to the emergency department with palpitations and lightheadedness. Her blood pressure is 88/56 mmHg and her telemetry shows a regular wide-complex tachycardia at 210 beats per minute with visible monomorphic flutter waves at the same rate and 1:1 AV conduction. Which of the following is the correct immediate management?
A) Immediate synchronized direct current cardioversion; this patient is hemodynamically unstable with a recognized flecainide proarrhythmia: AF organized to flutter at a slowed rate with 1:1 AV conduction because no AV nodal blocking agent was prescribed; electrical cardioversion is the correct first intervention; flecainide must be permanently discontinued afterward
B) Intravenous adenosine 6 mg rapid bolus to terminate the tachycardia; adenosine's ultra-short half-life makes it safe in this setting and will reveal the atrial flutter waves more clearly, allowing definitive diagnosis before cardioversion
C) Intravenous flecainide 2 mg/kg to restore sinus rhythm; the oral dose was insufficient to terminate the arrhythmia and an IV loading dose will increase plasma drug concentrations to achieve rhythm conversion
D) Intravenous metoprolol 5 mg over 2 minutes to achieve rate control; slowing the ventricular rate to below 150 beats per minute will improve hemodynamics while the flutter organizes back to atrial fibrillation spontaneously
E) Intravenous verapamil 5 mg to slow AV nodal conduction and reduce the ventricular rate; calcium channel blockade is preferred over beta-blockade in this setting because verapamil also has direct antiarrhythmic effects on the atrial flutter circuit
ANSWER: A
Rationale:
This is hemodynamically unstable flutter with 1:1 AV conduction ; a recognized and dangerous proarrhythmic complication of flecainide used without an AV nodal blocking agent. At a blood pressure of 88/56 mmHg the patient is compromised and immediate synchronized DC cardioversion is the correct first intervention, with no time for diagnostic drug trials. After cardioversion, flecainide must be permanently discontinued: it was improperly prescribed without a mandatory co-administered AV nodal blocking agent, and it has produced exactly the proarrhythmia this precaution is designed to prevent.
Option B: Option B is incorrect: adenosine is contraindicated in this context ; it is an AV nodal blocking agent and while it might transiently reveal flutter waves, it carries risk of accelerating conduction in an unstable patient; additionally, the diagnosis is already clear from the ECG and the priority is hemodynamic stabilization through cardioversion, not diagnostic drug administration.
Option C: Option C is incorrect: adding more flecainide to a patient with flecainide proarrhythmia is directly contraindicated; the drug must be stopped, not supplemented.
Option D: Option D is incorrect: metoprolol is an AV nodal blocking agent and while it would slow the ventricular rate, rate control alone without rhythm conversion is insufficient in a hemodynamically unstable patient at 210 beats per minute; cardioversion takes priority; additionally, beta-blockade in a patient with blood pressure of 88/56 mmHg risks further hemodynamic deterioration.
Option E: Option E is incorrect: verapamil is contraindicated in wide-complex tachycardia of uncertain origin because if the rhythm were ventricular tachycardia, verapamil would cause catastrophic hemodynamic collapse; verapamil does not have direct antiarrhythmic effects on atrial flutter circuits.
3. A 55-year-old man with atrial flutter at 300 beats per minute and 2:1 AV conduction (ventricular rate 150 beats per minute) is started on quinidine to convert to sinus rhythm. No AV nodal blocking agent is co-prescribed. Two hours after the first dose, his ventricular rate has increased to 240 beats per minute with a regular wide-complex pattern. Which of the following best explains this deterioration?
A) Quinidine has caused torsades de pointes by prolonging the QT interval; the regular wide-complex tachycardia represents stabilized polymorphic VT that has organized into a monomorphic pattern due to quinidine's sodium channel-stabilizing properties
B) Quinidine has produced complete AV block from excessive sodium channel blockade in the AV node, and the wide-complex rhythm at 240 beats per minute represents an accelerated junctional escape rhythm
C) Quinidine has paradoxically accelerated the flutter circuit by blocking potassium channels in the atria, shortening the atrial refractory period and increasing the flutter rate above 300 beats per minute
D) Quinidine has caused 1:1 flutter conduction by blocking AV nodal calcium channels, removing the rate-limiting calcium-dependent slow response that normally restricts conduction to 2:1 in flutter
E) Quinidine's use-dependent sodium channel block slowed the atrial flutter rate from 300 to approximately 240 beats per minute, while simultaneously its antimuscarinic properties removed vagal tone from the AV node, enhancing AV nodal conduction and allowing the now-slower flutter to conduct 1:1; this is precisely why an AV nodal blocking agent must always be co-prescribed with quinidine when treating atrial flutter
ANSWER: E
Rationale:
Two simultaneous pharmacological effects of quinidine combine to produce this dangerous outcome. First, quinidine's Class Ia use-dependent sodium channel block in atrial tissue slows the flutter rate from the typical 300 beats per minute toward 200 to 250 beats per minute. Second, quinidine's antimuscarinic (vagolytic) properties block muscarinic M2 receptors at the AV node, removing the physiological vagal brake on AV nodal conduction velocity and shortening AV nodal refractoriness. With the flutter now arriving at 240 beats per minute and the AV node conducting more rapidly due to loss of vagal tone, each flutter impulse traverses the AV node before the next arrives, producing 1:1 conduction at 240 beats per minute. The QRS complexes are wide because rate-dependent sodium channel accumulation is maximal at this ventricular rate. This outcome is entirely preventable: an AV nodal blocking agent must be established before quinidine is used for atrial flutter to prevent this 1:1 conduction catastrophe.
Option A: Option A is incorrect: while quinidine does prolong the QT interval and can cause TdP, the clinical scenario describes a regular wide-complex tachycardia at a rate consistent with 1:1 flutter conduction, not the irregular polymorphic morphology of TdP.
Option B: Option B is incorrect: quinidine's antimuscarinic properties actually enhance AV nodal conduction rather than block it; complete AV block is not this drug's characteristic effect; 240 beats per minute is far too fast for a junctional escape rhythm.
Option C: Option C is incorrect: quinidine slows the flutter rate through sodium channel block in atrial tissue, not accelerates it.
Option D: Option D is incorrect: quinidine does not block AV nodal calcium channels; its AV nodal effect is through antimuscarinic M2 blockade, not calcium channel antagonism.
4. A 68-year-old man is receiving a lidocaine infusion at 3 mg/min for sustained ventricular tachycardia that was successfully cardioverted. He suddenly reports circumoral numbness and tinnitus. His QRS is unchanged from baseline and blood pressure is 126/78 mmHg. Which of the following is the most appropriate immediate action?
A) Increase the lidocaine infusion rate to 4 mg/min; circumoral numbness and tinnitus during lidocaine infusion reflect subtherapeutic plasma concentrations producing paradoxical excitatory effects requiring higher drug concentrations
B) Reduce or stop the lidocaine infusion immediately; circumoral numbness and tinnitus are early signs of CNS toxicity at plasma concentrations of approximately 3 to 6 mcg/mL, representing a warning window before cardiac toxicity, which occurs at approximately 8 to 12 mcg/mL; prompt dose reduction can prevent progression to seizures and ventricular arrhythmias
C) Administer intravenous diazepam prophylactically before any reduction in lidocaine dose; prophylactic benzodiazepine is required to prevent breakthrough seizures during drug level correction in patients with early lidocaine CNS toxicity
D) Continue the infusion at the current rate and reassess in 15 minutes; circumoral numbness and tinnitus are common, benign side effects that resolve spontaneously as sodium channels reach steady-state saturation
E) Switch immediately to intravenous mexiletine; circumoral numbness indicates that lidocaine has exceeded its therapeutic range and the IV Class Ib alternative should replace the infusion
ANSWER: B
Rationale:
Circumoral numbness and tinnitus are early CNS symptoms of lidocaine toxicity, appearing at plasma concentrations of approximately 3 to 6 mcg/mL. The unchanged QRS and stable hemodynamics confirm that cardiac sodium channels are not yet significantly blocked ; cardiac toxicity requires concentrations of approximately 8 to 12 mcg/mL, two to four times the concentration producing CNS symptoms. This concentration gap is the clinical warning window: reducing or stopping the infusion immediately allows plasma concentrations to decline before cardiac toxicity supervenes.
Option A: Option A is incorrect: increasing the infusion rate would raise concentrations further toward the cardiac toxicity threshold; circumoral numbness is not a sign of subtherapeutic levels.
Option C: Option C is incorrect: prophylactic benzodiazepine before reducing the infusion is not the standard of care; the primary intervention is dose reduction, not pharmacological seizure prophylaxis.
Option D: Option D is incorrect: circumoral numbness and tinnitus are not benign or self-resolving at a fixed infusion rate; without dose reduction, concentrations may continue to rise toward cardiac toxicity.
Option E: Option E is incorrect: mexiletine is the oral Class Ib equivalent of lidocaine and has no intravenous formulation in clinical use; the correct action is dose reduction of the current lidocaine infusion.
5. A 64-year-old man has been on procainamide for 14 months for recurrent sustained VT. He presents with arthralgia, pleuritis, and a positive ANA titer of 1:320. His anti-double-stranded DNA antibody is negative. Which of the following correctly characterizes this complication?
A) The positive ANA with negative anti-dsDNA is inconsistent with procainamide-induced lupus; this serological profile is characteristic of hydralazine-induced lupus, not procainamide, which characteristically produces anti-dsDNA positivity in all cases
B) This patient requires permanent immunosuppressive therapy because procainamide-induced lupus is an irreversible autoimmune process that continues to progress after drug discontinuation
C) Slow acetylators are at lower risk for this complication because slow acetylation limits exposure to the immunogenic NAPA metabolite responsible for the autoimmune response
D) The positive ANA with negative anti-dsDNA is the characteristic serological profile of procainamide-induced drug-induced lupus-like syndrome (DILS), which is the key distinguishing feature from idiopathic SLE where anti-dsDNA is typically positive; slow acetylators are at substantially greater risk because they accumulate higher concentrations of procainamide and its immunogenic hydroxylamine metabolites; the syndrome is generally reversible after drug discontinuation
E) Procainamide should be continued because ANA positivity is an expected pharmacological effect that occurs in virtually all patients on long-term therapy and does not independently predict clinical drug-induced lupus; the pleuritis and arthralgia require separate investigation
ANSWER: D
Rationale:
Procainamide-induced DILS is identified by its characteristic serological profile: ANA positivity (developing in 50 to 80 percent of patients on chronic therapy) combined with absence of anti-dsDNA antibodies. The absence of anti-dsDNA is the key distinguishing feature from idiopathic SLE, where anti-dsDNA antibodies are typically present. Slow acetylators are at substantially greater risk because they metabolize procainamide to NAPA more slowly, accumulating higher concentrations of the parent drug and its immunogenic hydroxylamine intermediates that modify nuclear proteins and trigger the autoimmune response. The syndrome is generally reversible after drug discontinuation, though ANA titers may persist for months.
Option A: Option A is incorrect: the positive ANA with negative anti-dsDNA is precisely the characteristic profile of procainamide DILS; it is not inconsistent with this diagnosis.
Option B: Option B is incorrect: DILS is generally reversible after drug discontinuation; permanent immunosuppressive therapy is not required.
Option C: Option C is incorrect: slow acetylators are at greater risk, not lower risk; they accumulate more immunogenic parent compound and hydroxylamine metabolites.
Option E: Option E is incorrect: while ANA positivity alone is common in procainamide-treated patients, the combination of ANA positivity with clinical symptoms (pleuritis, arthralgia) constitutes DILS requiring drug discontinuation.
6. A 52-year-old woman with paroxysmal AF and mild intermittent asthma is started on propafenone for rhythm control. Two weeks later she presents with worsening dyspnea and wheeze confirmed as reversible airflow obstruction on spirometry. Which of the following best explains this complication?
A) Propafenone's sodium channel blocking properties have extended action potential duration in bronchial smooth muscle cells, producing sustained bronchoconstriction through the same mechanism as its cardiac antiarrhythmic effect
B) Propafenone's IKr-blocking properties have produced QT prolongation in bronchial airway epithelium, triggering calcium-dependent smooth muscle contraction as an off-target effect of its repolarization prolongation
C) Propafenone has weak beta-adrenergic blocking properties (approximately one-fortieth the potency of propranolol); in patients with reactive airway disease, even this modest degree of beta-2 receptor blockade can precipitate clinically significant bronchospasm; this distinguishes propafenone from flecainide, which has no beta-blocking activity and would not carry this risk
D) Propafenone's antimuscarinic properties paradoxically cause bronchoconstriction by blocking inhibitory M2 receptors on parasympathetic nerve terminals, disinhibiting acetylcholine release and increasing bronchial smooth muscle tone
E) Propafenone's alpha-adrenergic blocking properties have caused mast cell degranulation in bronchial tissue, triggering IgE-mediated allergic bronchospasm; this is a class effect of all Class Ic agents and would occur equally with flecainide
ANSWER: C
Rationale:
Propafenone is unique among Class Ic agents in possessing weak beta-adrenergic blocking properties, estimated at approximately one-fortieth the potency of propranolol. While modest, this beta-blocking activity is sufficient to produce clinically significant bronchospasm in patients with underlying reactive airway disease or asthma, where beta-2 receptor blockade in bronchial smooth muscle removes the bronchodilatory sympathetic tone. This adverse effect is a recognized contraindication that distinguishes propafenone from flecainide: patients with asthma or significant reactive airway disease should not receive propafenone, while flecainide, which has no beta-blocking activity, does not carry this risk. Management requires discontinuing propafenone and considering flecainide as an alternative if the patient has a structurally normal heart.
Option A: Option A is incorrect: propafenone's sodium channel blocking properties are cardiac; bronchospasm from cardiac sodium channel effects is not an established mechanism.
Option B: Option B is incorrect: propafenone does not have significant IKr-blocking properties and does not cause clinically significant QT prolongation; its primary ECG effect is QRS widening from sodium channel block.
Option D: Option D is incorrect: propafenone does not have antimuscarinic properties; anticholinergic effects are features of quinidine and disopyramide, not propafenone.
Option E: Option E is incorrect: propafenone does not have clinically significant alpha-adrenergic blocking properties in bronchial tissue; IgE-mediated allergic bronchospasm through alpha-blockade is pharmacologically fabricated; flecainide does not cause bronchospasm.
7. A 31-year-old woman with congenital long QT syndrome type 3 (LQT3) due to a gain-of-function SCN5A mutation has a baseline QTc of 508 ms despite adequate beta-blocker therapy and has experienced two syncopal episodes in the past year. Her electrophysiologist adds mexiletine 150 mg three times daily to her regimen. Six weeks later her QTc has decreased to 468 ms and she has been asymptomatic. Which of the following best explains the mechanistic basis for this improvement?
A) Mexiletine, as a Class Ib sodium channel blocker with rapid kinetics and preferential binding to inactivated sodium channels, specifically targets the persistent late inward sodium current (INa,late) generated by the gain-of-function SCN5A mutation; by reducing this abnormal depolarizing current during the action potential plateau, mexiletine shortens action potential duration and the QTc interval in this patient
B) Mexiletine activates IKr potassium channels through an allosteric mechanism that is potentiated by concurrent beta-blocker therapy; the combined IKr activation and beta-blockade restores normal repolarization reserve in LQT3 by compensating for the excess sodium current with augmented repolarizing potassium current
C) Mexiletine competes with the SCN5A gain-of-function mutation at the channel inactivation gate, physically displacing the mutant protein domain and restoring normal rapid inactivation kinetics; this gene-corrective mechanism explains why mexiletine is specifically effective in LQT3 but not in other sodium channelopathies
D) Mexiletine reduces the QTc by blocking L-type calcium channels in addition to sodium channels; the calcium channel-blocking effect reduces the depolarizing drive during the action potential plateau synergistically with the sodium channel block, producing greater QTc shortening than either mechanism alone
E) Mexiletine's Class Ib properties shorten the action potential duration in all ventricular myocytes by reducing peak sodium current (INa,peak) during phase 0; the shorter phase 0 upstroke produces a shorter action potential throughout the ventricle, reducing the QTc uniformly regardless of whether LQT3 or other mutations are present
ANSWER: A
Rationale:
LQT3 is caused by gain-of-function mutations in SCN5A that impair rapid sodium channel inactivation, resulting in a persistent late inward sodium current (INa,late) throughout the action potential plateau. This sustained depolarizing current extends action potential duration and produces QT prolongation. Mexiletine, as a Class Ib sodium channel blocker, has rapid binding and unbinding kinetics and preferential affinity for sodium channels in the inactivated state ; precisely the abnormal state in which LQT3 mutant channels dwell. By binding to and blocking these persistently inactivated channels, mexiletine reduces INa,late, curtails the abnormal depolarizing drive during the plateau phase, shortens action potential duration, and produces a measurable reduction in QTc. Clinical data consistently demonstrate QTc shortening of 30 to 50 ms in LQT3 patients on mexiletine, and this mechanistic targeting makes it a rational adjunct to beta-blocker therapy in this specific subtype. Crucially, this mechanism is subtype-specific: LQT1 and LQT2 involve deficient repolarizing potassium current (IKs and IKr loss-of-function respectively) rather than excess sodium current, and mexiletine has no therapeutic benefit in those subtypes.
Option B: Option B is incorrect: mexiletine does not activate IKr; it is a sodium channel blocker; there is no established allosteric IKr-activating mechanism for mexiletine.
Option C: Option C is incorrect: mexiletine does not physically displace mutant protein domains or correct the genetic defect; it pharmacologically blocks the abnormal current produced by the mutant channel without altering the channel protein itself.
Option D: Option D is incorrect: mexiletine does not have clinically significant L-type calcium channel blocking activity; this mechanism belongs to verapamil and diltiazem (Class IV agents); mexiletine's QTc shortening is mediated exclusively through INa,late blockade.
Option E: Option E is incorrect: mexiletine's mechanism in LQT3 is specifically through INa,late blockade, not through reduction of peak INa during phase 0; reducing peak INa would produce a shorter, lower-amplitude phase 0 upstroke but would not specifically address the plateau-phase persistent current responsible for QT prolongation; moreover, reducing peak INa in Brugada-susceptible patients would worsen that condition.
8. A 48-year-old man with paroxysmal atrial fibrillation and no structural heart disease has been on flecainide 100 mg twice daily with metoprolol for three months. He is clinically well and in sinus rhythm. Which of the following best describes the correct ongoing monitoring approach and the pharmacodynamic finding that would prompt dose reassessment?
A) Monthly serum flecainide levels should be obtained because toxicity correlates directly with plasma drug concentration; a level above 1.0 mcg/mL indicates accumulation requiring dose reduction regardless of the patient's clinical status or ECG findings
B) Serial ECGs at rest and ideally with exercise or ambulatory monitoring are the primary monitoring tool; use-dependent sodium channel block causes QRS widening that is proportional to heart rate ; a QRS increase of more than 25 percent above the pre-treatment baseline, particularly at faster heart rates, is the primary ECG warning sign of sodium channel toxicity and warrants dose reduction or discontinuation
C) Annual echocardiography is the primary monitoring tool for flecainide because its primary toxicity is progressive left ventricular dysfunction from cumulative sodium channel blockade in myocardial cells; a decline in LVEF of more than 5 percentage points from baseline requires immediate drug discontinuation
D) Monitoring is required only if the patient develops symptoms; asymptomatic patients on stable flecainide doses with no structural heart disease do not require any routine ECG or laboratory monitoring because Class Ic toxicity invariably presents with overt clinical manifestations before ECG changes
E) Monthly thyroid function tests and liver function tests are the primary monitoring requirements for flecainide because its primary long-term toxicity profile involves thyroid dysfunction from iodine content and hepatotoxicity from quinone metabolite accumulation
ANSWER: B
Rationale:
The primary pharmacodynamic monitoring tool for flecainide is the QRS duration, reflecting the degree of use-dependent sodium channel block in the His-Purkinje system and ventricular myocardium. Because flecainide's block is use-dependent ; accumulating proportionally with heart rate ; QRS widening is rate-dependent and is most prominent at faster rates. A QRS duration increase of more than 25 percent above the pre-treatment baseline (measured at comparable heart rates) is widely used as a clinical warning sign of excessive sodium channel toxicity, warranting dose reduction or discontinuation. Exercise ECG is particularly valuable because it reveals rate-dependent QRS widening that may not be apparent at resting rates, and ambulatory monitoring can capture QRS width across the range of daily heart rates. Resting ECG alone may underestimate the degree of use-dependent block if the patient's resting rate is slow.
Option A: Option A is incorrect: routine plasma flecainide level monitoring is not standard practice; flecainide does not have a well-established therapeutic drug monitoring protocol equivalent to digoxin or aminoglycosides; ECG-based monitoring of QRS duration is the primary approach.
Option C: Option C is incorrect: flecainide does not cause progressive left ventricular dysfunction through cumulative sodium channel blockade in structurally normal myocardium; echocardiographic monitoring is not the primary surveillance tool for flecainide toxicity.
Option D: Option D is incorrect: asymptomatic QRS widening can precede clinical arrhythmia and represents important early warning of toxicity; routine ECG monitoring is recommended for patients on Class Ic therapy, not only symptom-triggered assessment.
Option E: Option E is incorrect: thyroid dysfunction and hepatotoxicity from iodine content and quinone metabolites are adverse effects of amiodarone, not flecainide; flecainide does not contain iodine and does not cause thyroid or hepatic toxicity through these mechanisms.
9. A 71-year-old man in the cardiac care unit is receiving a lidocaine infusion at 2 mg/min for ventricular tachycardia suppression following direct current cardioversion (DCCV). Twenty minutes ago he reported circumoral numbness and tinnitus and the infusion was reduced to 1 mg/min. Now the nursing staff report that he has had a generalized tonic-clonic seizure lasting 45 seconds, which has self-terminated. His blood pressure is 110/68 mmHg and his cardiac monitor shows sinus rhythm with an unchanged QRS duration. Which of the following best explains the progression of events and the correct next step?
A) The seizure represents a cardiac manifestation of lidocaine toxicity because the drug at elevated concentrations blocks sodium channels in the motor cortex through the same mechanism as in ventricular myocardium; immediate direct current cardioversion is required because seizures from lidocaine invariably precede ventricular fibrillation within minutes
B) The seizure represents a paradoxical excitatory reaction from lidocaine inhibiting inhibitory interneurons in the limbic cortex; this is a distinct mechanism from concentration-dependent toxicity and occurs at therapeutic levels without preceding circumoral symptoms in approximately 5 percent of patients receiving lidocaine infusions
C) The seizure occurred because reducing the infusion from 2 mg/min to 1 mg/min caused a paradoxical rise in free lidocaine fraction by displacing the drug from alpha-1 acid glycoprotein binding sites; the correct management is to restore the infusion to 2 mg/min to re-establish protein binding equilibrium
D) The seizure represents progression along the predictable concentration-dependent CNS toxicity hierarchy of lidocaine: circumoral numbness and tinnitus at 3 to 6 mcg/mL represent the first stage; if the drug is not stopped or the dose not reduced sufficiently, concentrations rise to 5 to 9 mcg/mL where seizures occur; the infusion must be stopped immediately, benzodiazepine administered if seizures recur, and the patient monitored closely for cardiac toxicity as concentrations continue to decline
E) The seizure represents hypoglycemia precipitated by lidocaine's inhibition of hepatic gluconeogenesis through sodium channel blockade in hepatocytes; the correct immediate management is intravenous dextrose 50% regardless of the serum glucose level because lidocaine-induced hypoglycemia does not respond to standard glucose monitoring protocols
ANSWER: D
Rationale:
This sequence of circumoral numbness and tinnitus followed by seizure is the classic stepwise progression of lidocaine CNS toxicity. The initial symptoms at plasma concentrations of approximately 3 to 6 mcg/mL (circumoral numbness, tinnitus, slurred speech) were appropriately recognized and the dose reduced, but the reduction was insufficient to prevent further concentration accumulation to the seizure threshold of approximately 5 to 9 mcg/mL. The infusion must now be completely stopped. The unchanged QRS duration and stable hemodynamics confirm that cardiac sodium channels have not yet been significantly blocked ; concentrations remain below the cardiac toxicity threshold of approximately 8 to 12 mcg/mL. Benzodiazepines should be available for seizure recurrence. The patient must be closely monitored as lidocaine concentrations decline from the infusion discontinuation, because the clinical trajectory could still worsen before improving given the distribution kinetics. The cardiac rhythm must continue to be monitored for the possibility of conduction abnormalities as concentrations evolve.
Option A: Option A is incorrect: lidocaine seizures do not invariably precede ventricular fibrillation within minutes; the concentration hierarchy shows that cardiac toxicity requires substantially higher concentrations than seizures; the unchanged QRS here confirms the patient is not at imminent risk of cardiac toxicity; cardioversion is not indicated.
Option B: Option B is incorrect: circumoral symptoms and tinnitus did precede the seizure in this patient, disproving the claim that this is a paradoxical reaction at therapeutic levels without preceding symptoms; the progression is concentration-dependent, not paradoxical.
Option C: Option C is incorrect: protein binding displacement is not a clinically significant mechanism that causes paradoxical rises in free lidocaine after dose reduction; reducing the infusion rate reduces the plasma concentration over time; the seizure occurred because the dose reduction was too small and too slow to prevent concentration rise to the seizure threshold.
Option E: Option E is incorrect: lidocaine does not cause hypoglycemia through hepatic gluconeogenesis inhibition; this mechanism is not part of lidocaine's pharmacological profile; the presentation is CNS toxicity, not hypoglycemia.
10. A 77-year-old woman with a CrCl of 24 mL/min is receiving intravenous procainamide for sustained ventricular tachycardia following cardiac surgery. Her procainamide plasma level is 5.8 mcg/mL (within the therapeutic range of 4 to 8 mcg/mL). Her QTc on this morning's ECG is 522 ms, increased from 442 ms on admission, and her rhythm shows sinus tachycardia with no recurrent VT. Which of the following best explains the QTc prolongation and the correct management?
A) The QTc prolongation reflects toxic procainamide accumulation beyond the measured plasma level because the assay used by this hospital laboratory does not detect the protein-bound fraction; the true free procainamide concentration is two to three times the measured level, producing excessive IKr blockade and QTc prolongation; dose reduction to achieve a level below 4 mcg/mL is required
B) The QTc prolongation is a direct effect of the cardiac surgery itself, reflecting pericardial inflammation-mediated autonomic dysfunction that prolongs ventricular repolarization; the procainamide dose does not require adjustment and the QTc will normalize as the postoperative inflammatory response resolves over the next five to seven days
C) N-acetylprocainamide (NAPA), the principal active metabolite of procainamide formed by hepatic N-acetyltransferase 2 (NAT2), is eliminated almost entirely by the kidneys; in this patient with CrCl of 24 mL/min, NAPA clearance is severely reduced, causing accumulation to concentrations that produce QTc prolongation through IKr potassium channel blockade ; this complication occurs despite therapeutic procainamide levels because NAPA and procainamide are measured separately; procainamide should be discontinued and the NAPA level measured
D) The QTc prolongation reflects hypokalemia from perioperative diuresis, which reduces IKr current availability and extends ventricular repolarization independently of procainamide levels; correcting serum potassium to above 4.0 mEq/L will normalize the QTc without requiring any change to the procainamide regimen
E) The QTc prolongation is expected and acceptable on procainamide because the drug's Class Ia IKr-blocking properties produce predictable QT prolongation that parallels its antiarrhythmic effect; a QTc of 522 ms in a post-cardiac surgery patient represents a therapeutic response, not toxicity, and no dose change is required unless the QTc exceeds 550 ms
ANSWER: C
Rationale:
Procainamide is metabolized by N-acetyltransferase 2 (NAT2) to N-acetylprocainamide (NAPA), which has predominantly Class III pharmacological activity ; IKr potassium channel blockade ; without clinically significant sodium channel blocking activity. Unlike procainamide, which is cleared by both hepatic metabolism and renal excretion, NAPA is eliminated almost entirely by the kidneys. In a patient with CrCl of 24 mL/min, NAPA renal clearance is severely reduced and NAPA accumulates rapidly during procainamide infusion. Accumulated NAPA produces QTc prolongation through IKr blockade, which can cause torsades de pointes ; even when procainamide plasma levels remain within the therapeutic range, as in this patient. This is the key clinical trap: monitoring procainamide levels alone is insufficient in significant renal impairment; NAPA levels must also be measured, and procainamide should generally be avoided or used very cautiously when CrCl is below 30 to 40 mL/min. With a QTc of 522 ms, procainamide should be discontinued immediately.
Option A: Option A is incorrect: procainamide assays measure total drug and do not systematically underestimate free fractions in a clinically significant way; the explanation for the QTc prolongation despite therapeutic procainamide levels is NAPA accumulation, not assay error.
Option B: Option B is incorrect: while postoperative pericardial inflammation can affect autonomic tone, an 80 ms increase in QTc over the course of a procainamide infusion in a patient with severe renal impairment is a pharmacokinetic toxicity event, not an inflammatory autonomic phenomenon; discontinuing procainamide is the correct response.
Option D: Option D is incorrect: while hypokalemia should always be considered and corrected in a patient with QTc prolongation, the principal explanation here is NAPA accumulation; this is established by the combination of renal impairment, procainamide use, and QTc rise during infusion; potassium correction alone is insufficient management.
Option E: Option E is incorrect: a QTc of 522 ms is above the widely used 500 ms threshold associated with increased torsades de pointes risk; describing this as an acceptable therapeutic response is clinically incorrect; QTc prolongation of this degree on procainamide in a patient with severe renal impairment requires drug discontinuation.
11. A 49-year-old woman with obstructive hypertrophic cardiomyopathy (LVEF 75%, resting LVOT gradient 58 mmHg) develops symptomatic persistent atrial fibrillation. Her cardiologist starts disopyramide combined with metoprolol. After six weeks, her resting LVOT gradient has decreased to 22 mmHg and she is well rate-controlled in AF. Which property of disopyramide is responsible for the gradient reduction, and why is metoprolol essential in this regimen?
A) Disopyramide's pronounced negative inotropic effect reduces left ventricular contractility, directly decreasing the dynamic LVOT gradient driven by hypercontractile myocardium in HOCM; metoprolol is essential because disopyramide's antimuscarinic properties enhance AV nodal conduction, which would increase the ventricular rate in AF without the rate-limiting effect of the beta-blocker
B) Disopyramide's Class Ia IKr-blocking effect prolongs ventricular action potential duration and reduces contractility through a QT-dependent mechanism; metoprolol is added because IKr blockade alone increases TdP risk in hypertrophic myocardium and the beta-blocker reduces this proarrhythmic risk by preventing the pause-dependent trigger for torsades de pointes
C) Disopyramide's alpha-adrenergic blocking properties reduce systemic vascular resistance, lowering left ventricular afterload and allowing more complete systolic emptying that paradoxically reduces the outflow tract gradient; metoprolol prevents reflex tachycardia from the peripheral vasodilation
D) Disopyramide's direct calcium channel blocking properties in atrioventricular nodal cells slow conduction through the AV node and reduce the ventricular rate in AF; metoprolol is added because disopyramide cannot achieve adequate rate control alone in AF and the combination achieves synergistic AV nodal slowing
E) Disopyramide's sodium channel blocking effect in atrial tissue suppresses the AF triggers arising from pulmonary vein sleeve myocytes, converting the patient to sinus rhythm; metoprolol is added as standard heart rate management for patients with HOCM in sinus rhythm to reduce dynamic obstruction from exercise-induced tachycardia
ANSWER: A
Rationale:
Disopyramide occupies a specific and guideline-recognized niche in hypertrophic obstructive cardiomyopathy precisely because of its pronounced negative inotropic effect, which is the strongest of all Class Ia agents. The dynamic LVOT gradient in HOCM is generated by hypercontractile ventricular myocardium combined with the Venturi-mediated systolic anterior motion of the anterior mitral leaflet against the hypertrophied septum during systole. Disopyramide's negative inotropy reduces the force of ventricular contraction, diminishing the velocity of ejection through the outflow tract and reducing the Venturi effect and gradient. This is a therapeutic application of a property that is ordinarily the most dangerous adverse effect of disopyramide in other clinical contexts. Metoprolol is not merely adjunctive but essential: disopyramide has significant antimuscarinic (anticholinergic) properties that block vagal tone at the AV node, enhancing AV nodal conduction velocity. In AF, this would increase the ventricular rate ; directly opposing the goal of rate control. Metoprolol's AV nodal slowing through beta-1 blockade counteracts this vagolytic effect and achieves the rate control that disopyramide alone would worsen.
Option B: Option B is incorrect: while disopyramide does block IKr and prolongs QTc, the gradient reduction is from negative inotropy, not from a QT-dependent contractility mechanism; TdP risk reduction is not the primary rationale for the beta-blocker in this combination.
Option C: Option C is incorrect: disopyramide does not have clinically significant alpha-adrenergic blocking properties; this effect is associated with quinidine; disopyramide's LVOT gradient reduction is through negative inotropy.
Option D: Option D is incorrect: disopyramide does not provide AV nodal rate control through direct calcium channel blockade in the AV node; its AV nodal effect is antimuscarinic and actually enhances rather than slows nodal conduction.
Option E: Option E is incorrect: while disopyramide's sodium channel blockade does affect atrial tissue and may have some rhythm control effect, the specific demonstrated benefit in HOCM is gradient reduction through negative inotropy, not AF suppression through pulmonary vein trigger elimination.
12. A 51-year-old woman with paroxysmal atrial fibrillation, mild intermittent asthma well controlled on an inhaled corticosteroid, and no structural heart disease is evaluated for rhythm control therapy. Her cardiologist is choosing between flecainide and propafenone. Which of the following best guides the selection between these two Class Ic agents in this specific patient?
A) Propafenone is preferred because its weak beta-blocking property provides simultaneous AV nodal rate protection that would prevent 1:1 flutter conduction if AF converts to flutter, eliminating the need for a co-prescribed AV nodal blocking agent and simplifying the regimen
B) Flecainide is preferred because it lacks beta-adrenergic blocking activity; propafenone's weak but clinically relevant beta-blocking properties carry a risk of bronchospasm in a patient with pre-existing reactive airway disease, making it relatively contraindicated in this patient with asthma; flecainide must still be co-prescribed with a separate AV nodal blocking agent to prevent flutter 1:1 conduction
C) The two agents are pharmacologically equivalent in this patient; the mild asthma is not a relevant factor in selecting between flecainide and propafenone because neither drug has any pharmacological interaction with airway beta-adrenergic receptors at Class Ic antiarrhythmic doses
D) Propafenone is preferred because its additional calcium channel blocking properties reduce bronchial smooth muscle contractility, providing a protective effect against exercise-induced bronchospasm that makes it the safer Class Ic option for patients with reactive airway disease
E) Neither agent is appropriate; asthma of any severity is an absolute contraindication to all Class Ic antiarrhythmic agents because their sodium channel blocking effect in bronchial epithelial cells impairs mucociliary clearance and increases the risk of pneumonia; amiodarone should be used instead
ANSWER: B
Rationale:
Within the Class Ic subgroup, flecainide and propafenone share the same primary mechanism (slow-recovery sodium channel blockade) and the same structural heart disease contraindication, but differ in their secondary pharmacological properties. Propafenone has weak beta-adrenergic blocking activity (approximately one-fortieth the potency of propranolol) and weak calcium channel blocking activity. Even weak beta-blockade is sufficient to precipitate bronchospasm in patients with reactive airway disease through partial antagonism of beta-2 receptor-mediated bronchodilation. This makes propafenone relatively contraindicated in asthmatic patients. Flecainide has neither beta-blocking nor calcium channel blocking activity and does not affect airway beta-adrenergic receptors, making it the appropriate Class Ic choice in this patient. Crucially, flecainide must still be co-prescribed with a separate AV nodal blocking agent (beta-blocker, diltiazem, or verapamil ; with careful attention to the beta-blocker choice given the asthma) to prevent flutter 1:1 conduction; propafenone's beta-blocking effect does not replace this requirement and is not sufficient AV nodal protection on its own.
Option A: Option A is incorrect: propafenone's weak beta-blocking activity is not sufficient to reliably prevent flutter 1:1 conduction and does not eliminate the need for a co-prescribed AV nodal blocker; this is not an established clinical rationale for preferring propafenone in this context.
Option C: Option C is incorrect: propafenone's beta-blocking activity is clinically relevant in patients with reactive airway disease; the two drugs are not equivalent in this patient; asthma is a legitimate factor distinguishing flecainide from propafenone.
Option D: Option D is incorrect: propafenone's weak calcium channel blocking properties do not provide clinically significant bronchodilation or protection against exercise-induced bronchospasm; the beta-blocking risk outweighs any theoretical calcium channel benefit in asthmatic patients.
Option E: Option E is incorrect: asthma is not a contraindication to flecainide; Class Ic sodium channel blockade in cardiac tissue does not impair mucociliary clearance; this represents a fabricated mechanism.
13. A 59-year-old man is in the cardiac care unit following an acute anterior myocardial infarction complicated by sustained ventricular tachycardia. After DC cardioversion to sinus rhythm, the team initiates intravenous lidocaine for VT suppression. A student asks why lidocaine is preferred over flecainide for VT suppression in the acute ischemic setting. Which of the following best explains the pharmacodynamic rationale?
A) Lidocaine is preferred because it prolongs the QT interval through IKr blockade, which increases the effective refractory period in ventricular myocardium and makes re-entrant VT circuits non-sustainable; flecainide does not prolong the QT interval and therefore cannot terminate re-entrant circuits through this mechanism
B) Lidocaine is preferred because it has no effect on the AV node and therefore does not slow the ventricular rate in sinus rhythm, making it safer to use in patients who have not yet been rate-controlled after myocardial infarction
C) Lidocaine is preferred because its oral bioavailability exceeds 80 percent, allowing rapid conversion from intravenous to oral dosing within 24 hours of myocardial infarction for seamless transition to outpatient therapy; flecainide requires weeks of IV loading before oral therapy is effective
D) Lidocaine is preferred because its Class Ib rapid-recovery kinetics confer selective activity in ischemic myocardium: ischemic and depolarized cells maintain their sodium channels in the inactivated state for longer periods than normally polarized cells, and lidocaine ; which binds preferentially to inactivated channels ; achieves greater blockade in ischemic peri-infarct tissue than in surrounding normal myocardium; this selective suppression of abnormal conduction targets the re-entrant substrate while minimally affecting normal tissue; additionally, flecainide is contraindicated in post-MI structural disease by the CAST principle
E) Lidocaine is preferred because its Class Ib mechanism shortens action potential duration in ischemic myocardium, homogenizing repolarization across normal and ischemic zones and eliminating the dispersion of refractoriness that sustains re-entrant VT circuits; flecainide's longer recovery kinetics cannot achieve this repolarization homogenization
ANSWER: D
Rationale:
The preference for lidocaine over Class Ic agents in the acute ischemic VT setting is grounded in two complementary arguments. First, lidocaine's Class Ib pharmacodynamics confer a degree of selectivity for ischemic tissue: ischemic and hypoxic myocardium has a depolarized resting membrane potential and maintains sodium channels in the inactivated state for longer fractions of the cardiac cycle compared with normally polarized myocardium. Lidocaine, with its rapid kinetics and preferential affinity for inactivated channels, achieves greater proportional block in ischemic tissue than in adjacent normal myocardium. This pharmacodynamic selectivity means lidocaine suppresses abnormal conduction in the peri-infarct re-entrant substrate while having less impact on normal ventricular conduction, reducing the risk of creating new re-entrant circuits in normal tissue. Additionally, APD shortening by Class Ib agents may reduce the window for early afterdepolarization (EAD) formation. Second ; and critically ; Class Ic agents (flecainide, propafenone) are absolutely contraindicated in post-MI structural disease by the CAST principle: slow-recovery sodium channel blockade in heterogeneous ischemic myocardium dramatically increases proarrhythmic risk and mortality.
Option A: Option A is incorrect: lidocaine does not block IKr and does not prolong the QT interval; QT prolongation is the mechanism of Class Ia and III agents; lidocaine's antiarrhythmic mechanism is through sodium channel blockade with APD shortening, not QT-mediated refractoriness extension.
Option B: Option B is incorrect: lidocaine's AV nodal effect is not the rationale for its use over flecainide in post-MI VT; this reasoning is pharmacologically tangential.
Option C: Option C is incorrect: lidocaine has very poor oral bioavailability (approximately 3 percent) due to first-pass hepatic metabolism and must be maintained as IV infusion; mexiletine is the oral Class Ib equivalent; there is no rapid oral transition from IV lidocaine.
Option E: Option E is incorrect: while lidocaine does shorten APD, homogenizing repolarization across ischemic and normal zones is not the primary stated pharmacodynamic rationale for its preference; the primary argument is selective ischemic tissue targeting through inactivated channel affinity and the CAST contraindication of flecainide.
14. A 63-year-old man who had an anterior myocardial infarction eight months ago presents for a follow-up visit. His LVEF is 42%. His cardiologist at another institution started flecainide three months ago after a Holter monitor showed frequent premature ventricular beats that the patient found symptomatic. A repeat Holter now shows complete suppression of the PVBs and the patient reports feeling much better with resolution of his palpitations. His QRS duration has increased from 88 ms at baseline to 116 ms. Which of the following best represents the correct management?
A) Continue flecainide at the current dose; the QRS increase from 88 ms to 116 ms represents a 32 percent increase above baseline which exceeds the 25 percent warning threshold, but this is acceptable in a patient with demonstrated symptomatic benefit and complete PVB suppression; the benefit of symptom control outweighs the pharmacodynamic toxicity signal in post-MI patients with preserved LVEF above 40%
B) Continue flecainide and add amiodarone for additional antiarrhythmic protection; the 32 percent QRS widening indicates that flecainide is not fully controlling the underlying arrhythmic substrate, and adding a second antiarrhythmic agent will provide complementary mechanism coverage and reduce the residual arrhythmic risk
C) Discontinue flecainide immediately; this patient has structural heart disease from prior MI and Class Ic agents are contraindicated in this population regardless of current ejection fraction ; the CAST trial demonstrated that flecainide and encainide increased arrhythmic death and total mortality in post-MI patients despite effective PVB suppression; the symptomatic benefit from PVB suppression does not override the mortality risk; the 32 percent QRS widening is an additional toxicity signal; an alternative approach to symptom management should be discussed
D) Reduce the flecainide dose by 50 percent to resolve the QRS widening; once the QRS returns to within 25 percent of baseline, flecainide can continue safely in this patient because the CAST contraindication applies only to patients with LVEF below 40%, and this patient's LVEF of 42% places him above the threshold for safe Class Ic use
E) Continue flecainide and add a low-dose beta-blocker to prevent the AV nodal acceleration that may have contributed to his PVB burden; the combination of flecainide and beta-blocker has synergistic PVB-suppressing activity that will further reduce arrhythmic risk, and the beta-blocker's mortality benefit in post-MI patients offsets any residual Class Ic proarrhythmic risk
ANSWER: C
Rationale:
This case directly applies the CAST lesson to clinical practice. The CAST trial enrolled post-MI patients with asymptomatic or mildly symptomatic ventricular premature beats and demonstrated that flecainide and encainide significantly increased arrhythmic death and total mortality compared with placebo ; despite effectively suppressing PVBs. The trial established the principle that PVB suppression is an unreliable surrogate for clinical benefit and that Class Ic agents are contraindicated in structural heart disease from prior MI. This contraindication is not gated by ejection fraction: the patient's LVEF of 42% does not create a safe zone for Class Ic use. The ischemic scar substrate from prior MI is the contraindication regardless of current ventricular function. Flecainide must be discontinued immediately. The 32 percent QRS widening (from 88 to 116 ms) exceeds the 25 percent toxicity warning threshold and provides an additional pharmacodynamic reason for discontinuation. The patient's symptomatic benefit from PVB suppression is real and clinically meaningful, but this does not override the mortality risk established by CAST ; an important lesson in surrogate endpoint limitations. Alternative symptom management could include a beta-blocker, which carries a survival benefit in post-MI patients.
Option A: Option A is incorrect: the 32 percent QRS widening combined with the post-MI structural disease are both independent reasons to discontinue flecainide; there is no LVEF threshold above which these risks are acceptable.
Option B: Option B is incorrect: adding amiodarone to flecainide would compound drug toxicity and does not address the fundamental contraindication; the correct step is to remove flecainide.
Option D: Option D is incorrect: there is no LVEF threshold (above or below 40%) that makes flecainide safe in post-MI structural disease; the CAST contraindication applies to all such patients; dose reduction does not resolve the underlying mechanism of proarrhythmia.
Option E: Option E is incorrect: adding a beta-blocker to an ongoing contraindicated flecainide regimen does not offset the proarrhythmic risk; the flecainide must be stopped first; the beta-blocker could then be started independently for its established post-MI mortality benefit.
15. A 74-year-old man with sick sinus syndrome and symptomatic paroxysmal atrial fibrillation undergoes dual-chamber pacemaker implantation for symptomatic bradycardia. His cardiologist now wishes to add flecainide for AF rhythm control. A colleague states that flecainide is contraindicated in sick sinus syndrome. Which of the following best explains the correct reasoning and how the pacemaker changes the risk-benefit calculation?
A) The colleague is correct; flecainide remains absolutely contraindicated in sick sinus syndrome regardless of pacemaker status because the drug produces irreversible suppression of sinus node automaticity through sodium channel blockade in nodal pacemaker cells
B) The colleague is correct; flecainide is contraindicated because its use-dependent sodium channel block accumulates in pacemaker cells and produces complete sinus arrest that the pacemaker cannot reliably detect and respond to in time to prevent syncope
C) The colleague is incorrect; flecainide has no pharmacological effect on sinus node automaticity because the sinoatrial node depolarizes exclusively through calcium channels (If current), which are completely unaffected by Class I sodium channel blockers
D) The colleague is correct; the pacemaker does not alter the risk because flecainide's primary concern in sick sinus syndrome is not bradycardia but rather QT prolongation leading to torsades de pointes, a risk that the pacemaker cannot prevent
E) The colleague raises a valid concern: flecainide can suppress sinus node function and worsen bradycardia in patients with pre-existing sinus node disease; however, with a permanent pacemaker providing a reliable lower rate limit, this bradycardia risk is mitigated by guaranteed backup pacing; the pacemaker fundamentally changes the risk calculus, making flecainide a reasonable choice in this patient provided there is no structural heart disease
ANSWER: E
Rationale:
Flecainide and other Class Ic sodium channel blockers can suppress sinus node automaticity and worsen existing sinus node dysfunction, because although the SA node primarily depolarizes through calcium channels, flecainide affects pacemaker function through indirect effects on surrounding Purkinje-like cells and other mechanisms. In a patient with sick sinus syndrome without pacemaker backup, this sinus node suppression can cause symptomatic bradycardia, prolonged pauses, or sinus arrest. However, a permanent pacemaker with a programmed lower rate limit fundamentally changes this risk: if flecainide suppresses the dysfunctional sinus node, the pacemaker detects the resulting bradycardia and fires to maintain the minimum rate, preventing symptomatic episodes. This pacemaker safety net is the reason that flecainide can be appropriately used in sick sinus syndrome patients who have pacemakers ; a clinical scenario encountered in patients like this one who have both arrhythmia burdens (sick sinus syndrome and AF). Critically, the absence of structural heart disease must still be confirmed: the CAST-based contraindication applies independently of pacemaker status.
Option A: Option A is incorrect: flecainide's sinus node suppression is pharmacodynamic and reversible as drug concentrations decline; it does not produce irreversible automaticity suppression.
Option B: Option B is incorrect: pacemakers are specifically designed to detect and respond to bradycardia and pauses within milliseconds; rate detection is reliable and syncope from pacemaker-detectable pauses is extremely uncommon with modern device programming.
Option C: Option C is incorrect: while the SA node does depolarize primarily through calcium channels (HCN4 for the funny current and L-type calcium channels for the upstroke), flecainide does measurably affect sinus node function in patients with pre-existing sinus node disease through indirect mechanisms; the claim of no pharmacological effect is an overstatement.
Option D: Option D is incorrect: flecainide does not prolong the QT interval and does not cause torsades de pointes; QT prolongation is the proarrhythmic mechanism of Class Ia and Class III agents, not Class Ic agents; the primary concern with flecainide in sick sinus syndrome is bradycardia, not TdP.
16. A 66-year-old man with ischemic cardiomyopathy (LVEF 30%) and moderate hepatic congestion from right heart failure is receiving intravenous lidocaine for sustained VT suppression following cardioversion. He received an initial bolus of 1.5 mg/kg and is now on a maintenance infusion. His nurse asks why both a bolus and a continuous infusion are needed, and whether the dose should be adjusted for his cardiac and hepatic status. Which of the following best addresses both questions?
A) The bolus and infusion are needed because lidocaine has zero-order pharmacokinetics; a single bolus achieves a brief therapeutic plateau that must be maintained by a fixed-rate infusion delivering drug at exactly the same rate it is produced endogenously; hepatic congestion does not affect lidocaine dosing
B) The bolus achieves rapid therapeutic plasma concentrations because lidocaine distributes quickly into the central compartment; however, lidocaine's hepatic elimination half-life of approximately 90 to 120 minutes means that bolus-only levels decline rapidly below the therapeutic range; a continuous infusion is required to maintain steady-state concentrations; hepatic congestion from right heart failure reduces hepatic blood flow and lidocaine clearance, increasing the risk of drug accumulation ; a lower infusion rate should be used in this patient
C) The bolus and infusion together achieve a higher peak concentration than either alone; lidocaine's protein binding is saturated by the bolus, allowing the infusion to circulate as free drug at higher effective concentrations; right heart failure does not affect protein binding or lidocaine clearance
D) The bolus saturates sodium channels in ischemic ventricular tissue and a loading dose is necessary to fill this large tissue reservoir before a maintenance infusion can maintain adequate concentrations; reduced ejection fraction increases the volume of distribution proportionally, requiring a higher infusion rate to achieve therapeutic concentrations in this patient
E) The continuous infusion is not actually required; lidocaine's half-life of 8 to 12 hours means that a single loading bolus produces sustained therapeutic plasma concentrations for the first 24 hours; a continuous infusion is optional and used only in hemodynamically unstable patients who cannot tolerate the mild hypotension associated with repeat bolus dosing
ANSWER: B
Rationale:
Lidocaine's pharmacokinetic profile requires both a loading bolus and a continuous infusion for sustained VT suppression. A single bolus rapidly achieves therapeutic plasma concentrations through distribution into the central compartment (including cardiac tissue), but lidocaine is eliminated by hepatic metabolism with a terminal half-life of approximately 90 to 120 minutes. Without a maintenance infusion, plasma concentrations fall below the therapeutic range of 1.5 to 5 mcg/mL within one to two hours of the bolus. A continuous infusion at 1 to 4 mg/min maintains concentrations in the therapeutic range. Hepatic clearance is the critical dose-adjustment factor in this patient: right heart failure produces hepatic venous congestion that reduces hepatic blood flow and hepatic intrinsic clearance, impairing lidocaine metabolism. Additionally, reduced cardiac output in HFrEF (LVEF 30%) reduces hepatic blood flow further. Both factors decrease lidocaine clearance, causing drug accumulation at standard infusion rates. A lower infusion rate (typically 1 to 2 mg/min rather than 3 to 4 mg/min) is appropriate in patients with significant hepatic congestion or reduced cardiac output.
Option A: Option A is incorrect: lidocaine does not have zero-order pharmacokinetics at therapeutic doses; it undergoes first-order hepatic elimination; the infusion is needed because of first-order decay from a finite half-life, not to replace endogenous production.
Option C: Option C is incorrect: protein binding saturation is not the pharmacokinetic rationale for the bolus-infusion approach; the bolus achieves rapid therapeutic concentrations through fast central-compartment distribution, and hepatic congestion does affect clearance significantly.
Option D: Option D is incorrect: while reduced cardiac output in HFrEF can reduce the volume of distribution (not increase it) by reducing peripheral tissue perfusion, the primary concern in this patient is reduced clearance requiring a lower infusion rate, not higher; increased infusion rates in HFrEF risk toxicity.
Option E: Option E is incorrect: lidocaine's terminal half-life is 90 to 120 minutes, not 8 to 12 hours; a single bolus produces adequate levels for only one to two hours; continuous infusion is required for sustained VT suppression.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.